Acer Therapeutics — Opexa Therapeutics — Q1 2013 Earnings Presentation
9 slides from Acer Therapeutics's earnings presentation, May 14, 2013
Slide 1: First Quarter 2013 Earnings Update Call
Precision Immunotherapy TM Opexa Therapeutics, Inc. First Quarter 2013 Earnings Update Call 14 May 2013 NASDAQ: OPXA
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This earnings presentation contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements contained in this
Slide 3: Opexa's Mission
3 Opexa’s Mission To lead the field of Precision ImmunotherapyTM by aligning the interests of patients, employees and shareholders.
Slide 4: Tcelna Addressing the Root Cause of Multiple Sclerosis; the Role of Myelin Reactive T Cells
4 Tcelna™ Addressing the Root Cause of Multiple Sclerosis; the Role of Myelin Reactive T Cells (MRTCs) • The Oligodendroglial cells play a vital role in the production of myelin, the protective coating of nerve fibers • When MRTCs cross the blood brain barrier and bind to the Antigen Presenting Cell
Slide 5: Tcelna in Secondary Progressive Multiple Sclerosis
5 TcelnaTM in Secondary Progressive Multiple Sclerosis • Patients initially experience a relapsingremitting course then transition to SPMS • SPMS patients experience worsening QOL / disability with or without relapses • Over 400,000 patients in U.S. and over 1 million world wide have MS • Approximat
Slide 6: Merck Serono Agreement for MS indication
6 Merck Serono Agreement for MS indication • Feb 2013 option and license agreement with Merck Serono – Up to $220 million in additional milestone payments • Option exercise $25 million for starting Phase III/ or $15 million if another Phase II • $35 million FDA filing, approval and commercialized in
Slide 7: Financials
7 Financials Income Statement Q1 2013 Q1 2012 Option Revenue $220,100 - Research & Development $1,621,366 $1,490,097 General & Administrative $1,102,435 $816,196 Earnings Per Share $ (0.58) $ (0.41) Balance Sheet Details March 31, 2013 Dec 31, 2013 Cash $7,834,336 $592,004 Basic Shares as of 05/10 8
Slide 8: Abili-T: Landmark trial in SPMS
8 Abili-T TM: Landmark trial in SPMS • Abili-T Phase IIb clinical trial in SPMS is ongoing – Double-blind, 1:1 randomized, placebo-controlled – Inclusion criteria: Secondary Progressive MS with EDSS of 3 to 6 – 48 patients enrolled at April 30, 2013 – Immune Monitoring program conducted on a blinded
Slide 9: Investment Thesis
9 Investment Thesis • Platform company • Esteemed Scientific Advisory Board • Precision therapy potentially maximizes efficacy and minimizes safety • Targeting an unmet medical need with a substantial potential revenue opportunity • Option Agreement recently secured with strong Pharma company • Repl